Revenue ($USD) : $330,379,000
R&D spend : $57,337,000.00
Employees : 1,050
Fiscal year end : 12/31/22
CEO : Michael Carrel

AtriCure develops devices for atrial fibrillation (AFib) and related conditions. AtriCure has carved out a strong niche for itself in the surgical space. Its Isolator Synergy ablation clamp is the only device — catheter-delivered or surgical — that is FDA-approved for the treatment of persistent and long-standing persistent AFib. In addition, AtriCure’s AtriClip left atrial appendage (LAA) exclusion products provide an option for surgeons to reduce stroke risk after heart operations. AtriCure’s Hybrid AF therapy is a minimally invasive procedure for persistent AFib patients, while its cryoablation technology blocks pain in cardiac and thoracic procedures. –CN and BB